Bolt Biotherapeutics to present clinical data from Phase 1/2 study of BDC-1001

Bolt Biotherapeutics announced that updated clinical data from its Phase 1/2 dose-escalation study of BDC-1001 will be presented in a mini-oral presentation at the European Society for Medical Oncology, ESMO, Congress 2023, being held in Madrid, Spain and virtually from October 20-24, 2023. BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate in development for the treatment of patients with human epidermal growth factor receptor 2-positive cancer. The ESMO presentation will include new results from the recently completed first-in-human Phase 1/2 dose-escalation study of BDC-1001 in patients with advanced HER2-expressing solid tumors. “The upcoming presentation at ESMO builds on the positive data we presented at ASCO 2023 with additional insights into efficacy, safety, and biomarkers. These data provide further support for the recommended Phase 2 dose being used in the ongoing Phase 2 study of BDC-1001,” said Edith A. Perez, Chief Medical Officer of Bolt Biotherapeutics. “We are proud of the significant progress we have made with BDC-1001 and these latest data reinforce that Boltbody(TM) ISACs can activate a patient’s immune system to fight cancer. We continue to advance BDC-1001 through the Phase 2 clinical studies in four HER2-positive solid tumor types.”